{"id":"NCT02315872","sponsor":"Providence Health & Services","briefTitle":"ACTH for Fatigue in Multiple Sclerosis Patients","officialTitle":"The Effect of ACTH (Acthar) on Measures of Chronic Fatigue in Patients With Relapsing Multiple Sclerosis.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-05-22","primaryCompletion":"2017-06-20","completion":"2018-12-13","firstPosted":"2014-12-12","resultsPosted":"2019-08-13","lastUpdate":"2019-09-09"},"enrollment":8,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis, Relapsing-Remitting"],"interventions":[{"type":"DRUG","name":"ACTH","otherNames":["Acthar Gel","Repository Corticotropin Injection"]},{"type":"DRUG","name":"Placebo","otherNames":["Control"]}],"arms":[{"label":"ACTH","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a study of Acthar gel (ACTH) in patients with relapsing multiple sclerosis who are experiencing chronic fatigue.","primaryOutcome":{"measure":"Fatigue at 28 Weeks","timeFrame":"28 weeks","effectByArm":[{"arm":"ACTH","deltaMin":56.5,"sd":null},{"arm":"Placebo","deltaMin":29,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":17},"locations":{"siteCount":5,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://oregon.providence.org/our-services/p/providence-brain-and-spine-institute/"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":4},"commonTop":["injection site reaction","bronchitis","Sinus infection","Flu","insomnia"]}}